JPH09512559A - 分子内環化によるカンプトテシン誘導体の製造 - Google Patents
分子内環化によるカンプトテシン誘導体の製造Info
- Publication number
- JPH09512559A JPH09512559A JP7528482A JP52848295A JPH09512559A JP H09512559 A JPH09512559 A JP H09512559A JP 7528482 A JP7528482 A JP 7528482A JP 52848295 A JP52848295 A JP 52848295A JP H09512559 A JPH09512559 A JP H09512559A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- dihydro
- compound
- ylmethyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 化学名”7−(4−メチルピペラジノメチレン)−10,11−エチレ ンジオキシ−20(R,S)−カンプトテシン”で知られる式(I′)のカンプ トテシン誘導体 の製造法あって、式(II′)の化合物 (式中、Xはハロゲン、特にクロロ、ブロモ、またはヨードである) を環化し、そして式(I′)の化合物が光学対掌体の混合物として得られるとき は、混合物を分割して所望の光学対掌体を得てもよく;および/または、所望な らば、得られた式(I′)の化合物もしくはその塩を生理学的に許容される塩もし くはその溶媒和物に変えることを含む、製造法。 2. 化学名”7−(4−メチルピペラジノメチレン)−10,11−エチレ ンジオキシ−20(S)−カンプトテシン”で知られる式(I)のカンプトテシ ン誘導体 の製造法であって、式(II)の化合物 (式中、Xはハロゲン、特にクロロ、ブロモ、またはヨードである) を環化し、そして、所望ならば、得られた式(I)の化合物またはその塩を生理学 的に許容される塩またはその溶媒和物に変えることを含む、製造法。 3. 環化プロセスをパラジウム触媒の存在下、塩基性条件下で行う、請求項 1または請求項2に記載の方法。 4. パラジウム触媒が酢酸パラジウム(II)である、請求項1−3のいずれ か一項に記載の方法。 5. パラジウム触媒用リガンドの存在下で行う、請求項3または請求項4に 記載の方法。 6. リガンドがトリフェニルホスフィン、トリ−o−トリルホスフィン、ト リ−m−トリルホスフィンまたはトリ−p−トリルホスフィンである、請求項5 に記載の方法。 7. 環化プロセスをアルカリ土類金属炭酸塩の存在下で行う、請求項1−6 のいずれか一項に記載の方法。 8. アルカリ土類金属炭酸塩が炭酸カリウムである、請求項7に記載の方法 。 9. 環化プロセスを極性非プロトン性溶媒中で行う、請求項1−8のいずれ か一項に記載の方法。 10. 溶媒がアセトニトリルまたはジメチルホルムアミドである、請求項9 に記載の方法。 11. 相転移触媒の存在下で行う、請求項1−10のいずれか一項に記載の 方法。 12. 不活性雰囲気中で行う、請求項1−11のいずれか一項に記載の方法 。 13. 不活性雰囲気が窒素またはアルゴンである、請求項12に記載の方法 。 14. 反応を高温で行う、請求項1−13のいずれか一項に記載の方法。 15. 反応をラジカル開始剤の存在下、遊離ラジカル環化プロセスによって 行う、請求項1または請求項2に記載の方法。 16. 反応をトルエンのような溶媒中で行う、請求項15に記載の方法。 17. 反応をスズ水素化物の存在下で行う、請求項15または請求項16に 記載の方法。 18. 反応を高温で行う、請求項15−17のいずれか一項に記載の方法。 19. 4(S)−4−エチル−4−ヒドロキシ−7−[7−ヨード−9−( 4−メチルピペラジン−1−イルメチル)−2,3−ジヒドロ[1,4]ジオキ シノ[2,3−g]キノリン−8−イルメチル]−4,7−ジヒドロ−1H−ピ ラノ[3,4−c]ピリジン−3,8−ジオンを環化し、および/または、所望 ならば、得られた化合物を生理学的に許容されるその塩に変えることを含む、7 −(4−メチルピペラジノメチレン)−10,11−エチレンジオキシ−20 (S)−カンプトテシンの製造法。 20. 環化を酢酸パラジウム、炭酸カリウム、トリフェニルホスフィンおよ びアセトニトリルの存在下で行う、請求項19に記載の方法。 21. 式(II′)の化合物 (式中、Xはハロゲンである) またはその塩もしくは溶媒和物。 22. Xがブロモまたはヨードである、請求項21に記載の化合物。 23. 式(II)の請求項21または請求項22に記載の化合物 24. 4(S)−4−エチル−4−ヒドロキシ−7−[7−ヨード−9−( 4−メチルピペラジン−1−イルメチル)−2,3−ジヒドロ[1,4]ジオキ シノ[2,3−g]キノリン−8−イルメチル]−4,7−ジヒドロ−1H−ピ ラノ[3,4−c]ピリジン−3,8−ジオン、またばその塩もしくは溶媒和物 。 25. 4(S)−4−エチル−4−ヒドロキシ−7−[7−ブロモ−9−( 4−メチルピペラジン−1−イルメチル)−2,3−ジヒドロ[1,4]ジオキ シノ[2,3−g]キノリン−8−イルメチル]−4,7−ジヒドロ−1H−ピ ラノ[3,4−c]ピリジン−3,8−ジオン、またはその塩もしくは溶媒和物 。 26. 4(S)−4−エチル−4−ヒドロキシ−7−[7−クロロ−9−( 4−メチルピペラジン−1−イルメチル)−2,3−ジヒドロ[1,4]ジオキ シノ[2,3−g]キノリン−8−イルメチル]−4,7−ジヒドロ−1H−ピ ラノ[3,4−c]ピリジン−3,8−ジオン、またはその塩もしくは溶媒化物 。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/237,081 | 1994-05-03 | ||
| US08/237,081 US5491237A (en) | 1994-05-03 | 1994-05-03 | Intermediates in pharmaceutical camptothecin preparation |
| PCT/US1995/005427 WO1995029919A1 (en) | 1994-05-03 | 1995-05-02 | Preparation of a camptothecin derivative by intramolecular cyclisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09512559A true JPH09512559A (ja) | 1997-12-16 |
Family
ID=22892263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7528481A Ceased JPH09512558A (ja) | 1994-05-03 | 1995-05-02 | 医薬用カンプトテシン製造用中間体 |
| JP7528482A Pending JPH09512559A (ja) | 1994-05-03 | 1995-05-02 | 分子内環化によるカンプトテシン誘導体の製造 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7528481A Ceased JPH09512558A (ja) | 1994-05-03 | 1995-05-02 | 医薬用カンプトテシン製造用中間体 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US5491237A (ja) |
| EP (3) | EP0758333B1 (ja) |
| JP (2) | JPH09512558A (ja) |
| AT (3) | ATE227292T1 (ja) |
| AU (2) | AU2381695A (ja) |
| DE (3) | DE69532634T2 (ja) |
| DK (1) | DK0758335T3 (ja) |
| ES (3) | ES2188661T3 (ja) |
| WO (2) | WO1995029919A1 (ja) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519234A (ja) * | 1999-12-29 | 2003-06-17 | リサーチ・トライアングル・インスティチュート | トポイソメラーゼI阻害を有するカンプトテシンβ−アラニンエステル |
| WO2006132296A1 (ja) * | 2005-06-09 | 2006-12-14 | Kabushiki Kaisha Yakult Honsha | 三環性ケトンの製造方法 |
| JP2008531487A (ja) * | 2005-02-22 | 2008-08-14 | エフ.ホフマン−ラ ロシュ アーゲー | カンプトセシンサブユニットの新規の合成法 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559309B2 (en) | 1996-11-01 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Preparation of a camptothecin derivative by intramolecular cyclisation |
| US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| EP1488809A1 (en) | 2001-01-16 | 2004-12-22 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer |
| US6809210B2 (en) | 2001-06-12 | 2004-10-26 | Lucent Technologies Inc. | Method of solvating a metal in an aromatic organic liquid |
| US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
| CZ299329B6 (cs) * | 2003-08-26 | 2008-06-18 | Pliva-Lachema A.S. | Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu |
| CZ299593B6 (cs) * | 2003-12-16 | 2008-09-10 | Pliva-Lachema A. S. | Zpusob výroby 7-ethyl-10-hydroxykamptothecinu |
| US8492456B2 (en) * | 2004-02-09 | 2013-07-23 | Hewlett-Packard Development Company, L.P. | Ink compositions for ink-jet printing |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| US20110129550A1 (en) | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| KR101530402B1 (ko) * | 2007-10-09 | 2015-06-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora) |
| AR074199A1 (es) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
| NZ594064A (en) | 2009-01-30 | 2012-08-31 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| ES2638323T3 (es) | 2009-05-20 | 2017-10-19 | Glaxosmithkline Llc | Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa |
| CN101591342B (zh) * | 2009-07-03 | 2011-07-27 | 华东师范大学 | 用于喜树碱类化合物制备的关键中间体合成方法 |
| WO2011025859A1 (en) | 2009-08-26 | 2011-03-03 | Cylene Pharmaceuticals, Inc. | Condensed quinolines as protein kinase modulators |
| US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
| KR101594002B1 (ko) | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Pi3 키나제 억제제로서의 벤즈이미다졸 유도체 |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產(第二)有限公司 | 新穎醫藥組成物 |
| HK1202450A1 (zh) | 2011-11-22 | 2015-10-02 | Deciphera Pharmaceuticals, Llc. | 表現出抗癌和抗增殖活性的吡啶酮酰胺以及類似物 |
| BR112014019034A8 (pt) | 2012-01-31 | 2017-07-11 | Smithkline Beecham Cork Ltd | Método para tratamento de câncer |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| PE20151024A1 (es) | 2012-11-30 | 2015-07-27 | Glaxosmithkline Llc | Composicion farmaceutica novedosa |
| US20150342957A1 (en) | 2013-01-09 | 2015-12-03 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination |
| WO2014108858A1 (en) | 2013-01-10 | 2014-07-17 | Glaxosmithkline Intellectual Property (No.2) Limited | Fatty acid synthase inhibitors |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| US20160361309A1 (en) | 2014-02-26 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
| WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| EP3331919A1 (en) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| ES2913208T3 (es) | 2015-12-01 | 2022-06-01 | Glaxosmithkline Ip Dev Ltd | Tratamientos de combinación y usos y métodos de los mismos |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| EP3494140A1 (en) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos and anti-pd-1 antibody combination therapy |
| CN110225983A (zh) | 2016-12-01 | 2019-09-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
| CN110831582B (zh) | 2017-07-05 | 2023-08-11 | 诺华股份有限公司 | 药物组合物 |
| UY37866A (es) | 2017-09-07 | 2019-03-29 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp. |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| CN113795512A (zh) | 2019-02-01 | 2021-12-14 | 葛兰素史克知识产权开发有限公司 | 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法 |
| CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| EP4096718A1 (en) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| CN115073408A (zh) * | 2022-08-09 | 2022-09-20 | 江苏法安德医药科技有限公司 | 一种2,3,4,6-四苄基-d-吡喃葡萄糖的合成方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE152774C (ja) * | ||||
| US4399282A (en) * | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| DD152774A1 (de) * | 1980-08-25 | 1981-12-09 | Brunhilde Gorski | Verfahren zur abtrennung von palladium und technetium aus loesungen der kernbrennstoffwiederaufbereitung |
| US4399276A (en) * | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4413118A (en) * | 1981-03-02 | 1983-11-01 | Merck & Co., Inc. | Process for removal of homogeneous catalyst group VIII metals from process streams |
| US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| EP0220601B1 (en) * | 1985-10-21 | 1991-12-11 | Daiichi Seiyaku Co., Ltd. | Pyranoindolizine derivatives and preparation process thereof |
| JPS6314824A (ja) * | 1986-07-04 | 1988-01-22 | Tanaka Kikinzoku Kogyo Kk | 貴金属元素の回収方法 |
| JPS6333355A (ja) * | 1986-07-29 | 1988-02-13 | Mitsui Toatsu Chem Inc | シスチンの精製方法 |
| US5053512A (en) * | 1987-04-14 | 1991-10-01 | Research Triangle Institute | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives |
| US4981968A (en) * | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US5106742A (en) * | 1987-03-31 | 1992-04-21 | Wall Monroe E | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US5122526A (en) * | 1987-03-31 | 1992-06-16 | Research Triangle Institute | Camptothecin and analogs thereof and pharmaceutical compositions and method using them |
| US5244903A (en) * | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US4894456A (en) * | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US5227380A (en) * | 1987-03-31 | 1993-07-13 | Research Triangle Institute | Pharmaceutical compositions and methods employing camptothecins |
| US5180722A (en) * | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
| US5122606A (en) * | 1987-04-14 | 1992-06-16 | Research Triangle Institute | 10,11-methylenedioxy camptothecins |
| US5049668A (en) * | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| US5126494A (en) * | 1988-01-11 | 1992-06-30 | Massachusetts Institute Of Technology | Methods for catalytic asymmetric dihydroxylation of olefins |
| DE68924418T2 (de) * | 1988-01-11 | 1996-03-28 | Massachusetts Inst Technology | Durch komplexmittel beschleunigte katalytische asymmetrische dihydroxylierung. |
| US5227543A (en) * | 1988-01-11 | 1993-07-13 | Massachusetts Institute Of Technology | Facilitation of turnover in the ADH by additives which catalyze the hydrolysis of the OS(VI) glycolate esters |
| US5260461A (en) * | 1988-01-11 | 1993-11-09 | Massachusetts Institute Of Technology | Ligands for ADH: cinchona alkaloids and moderately sized organic substituents linked through a planar aromatic spacer group |
| US4965364A (en) * | 1988-02-23 | 1990-10-23 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation |
| US4871855A (en) * | 1988-01-11 | 1989-10-03 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation using dihydroquinidine and dihydroquinidine esters as ligands |
| JPH0615547B2 (ja) * | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| ES2165346T3 (es) * | 1989-09-15 | 2002-03-16 | Res Triangle Inst | Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina. |
| US5099047A (en) * | 1989-11-17 | 1992-03-24 | Mitsubishi Kasei Corporation | Method for recovering a group viii metal solid complex and hydroformylation method |
| CA2095219A1 (en) * | 1990-10-31 | 1992-05-01 | Hameed S. Allaudeen | Substituted indolizino[1,2-b]quinolinones |
| US5247089A (en) * | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5264579A (en) * | 1990-12-20 | 1993-11-23 | North Carolina State University | D ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5243050A (en) * | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5258516A (en) * | 1990-12-20 | 1993-11-02 | Nc State University | Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs |
| US5315007A (en) * | 1990-12-20 | 1994-05-24 | North Carolina State University | Process for making DE ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5212317A (en) * | 1990-12-20 | 1993-05-18 | North Carolina State University | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs |
| US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5254690A (en) * | 1990-12-20 | 1993-10-19 | North Carolina State University | Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs |
| US5162532A (en) * | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| EP0543969A1 (en) * | 1991-05-13 | 1993-06-02 | Massachusetts Institute Of Technology | Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins |
| DK0540099T3 (da) * | 1991-10-29 | 1996-06-17 | Glaxo Wellcome Inc | Vandopløselige camptothecinderivater |
| EP0556585A3 (en) * | 1992-01-24 | 1993-09-01 | Takeda Chemical Industries, Ltd. | Condensed camptothecin derivatives their production and use as antitumor agents |
| WO1993016698A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | SUBSTITUTED FURO[3',4':6,7]INDOLIZINO[1,2-b]QUINOLINONES |
| CA2142831A1 (en) * | 1992-08-21 | 1994-03-03 | Arthur B. Pardee | Treatment of human viral infections |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5479108A (en) * | 1992-11-25 | 1995-12-26 | David Cheng | Method and apparatus for handling wafers |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| WO1997016454A1 (en) * | 1995-11-02 | 1997-05-09 | Glaxo Wellcome Inc. | Method for preparing camptothecin derivatives |
-
1994
- 1994-05-03 US US08/237,081 patent/US5491237A/en not_active Expired - Lifetime
-
1995
- 1995-05-02 JP JP7528481A patent/JPH09512558A/ja not_active Ceased
- 1995-05-02 AT AT95918904T patent/ATE227292T1/de not_active IP Right Cessation
- 1995-05-02 EP EP95917217A patent/EP0758333B1/en not_active Expired - Lifetime
- 1995-05-02 AU AU23816/95A patent/AU2381695A/en not_active Abandoned
- 1995-05-02 ES ES95918904T patent/ES2188661T3/es not_active Expired - Lifetime
- 1995-05-02 JP JP7528482A patent/JPH09512559A/ja active Pending
- 1995-05-02 WO PCT/US1995/005427 patent/WO1995029919A1/en not_active Ceased
- 1995-05-02 AU AU24651/95A patent/AU2465195A/en not_active Abandoned
- 1995-05-02 DK DK95918904T patent/DK0758335T3/da active
- 1995-05-02 WO PCT/US1995/005425 patent/WO1995029917A2/en not_active Ceased
- 1995-05-02 US US08/737,032 patent/US6063923A/en not_active Expired - Fee Related
- 1995-05-02 ES ES95917217T patent/ES2219661T3/es not_active Expired - Lifetime
- 1995-05-02 EP EP95918904A patent/EP0758335B1/en not_active Expired - Lifetime
- 1995-05-02 DE DE69532634T patent/DE69532634T2/de not_active Expired - Fee Related
- 1995-05-02 US US08/732,435 patent/US5840898A/en not_active Expired - Fee Related
- 1995-05-02 AT AT02014439T patent/ATE289608T1/de not_active IP Right Cessation
- 1995-05-02 DE DE69534029T patent/DE69534029T2/de not_active Expired - Fee Related
- 1995-05-02 EP EP02014439A patent/EP1254908B9/en not_active Expired - Lifetime
- 1995-05-02 DE DE69528762T patent/DE69528762T2/de not_active Expired - Fee Related
- 1995-05-02 AT AT95917217T patent/ATE260919T1/de not_active IP Right Cessation
- 1995-05-02 ES ES02014439T patent/ES2238523T3/es not_active Expired - Lifetime
-
2000
- 2000-04-19 US US09/552,214 patent/US6462196B1/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003519234A (ja) * | 1999-12-29 | 2003-06-17 | リサーチ・トライアングル・インスティチュート | トポイソメラーゼI阻害を有するカンプトテシンβ−アラニンエステル |
| JP2008531487A (ja) * | 2005-02-22 | 2008-08-14 | エフ.ホフマン−ラ ロシュ アーゲー | カンプトセシンサブユニットの新規の合成法 |
| WO2006132296A1 (ja) * | 2005-06-09 | 2006-12-14 | Kabushiki Kaisha Yakult Honsha | 三環性ケトンの製造方法 |
| EA013473B1 (ru) * | 2005-06-09 | 2010-04-30 | Кабушики Каиша Якулт Хонша | Способ получения трициклического кетона |
| US8067595B2 (en) | 2005-06-09 | 2011-11-29 | Kabushiki Kaisha Yakult Honsha | Process for producing tricyclic ketone |
| US8466287B2 (en) | 2005-06-09 | 2013-06-18 | Kabushiki Kaisha Yakult Honsha | Process for producing tricyclic ketone |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE260919T1 (de) | 2004-03-15 |
| EP1254908B1 (en) | 2005-02-23 |
| ATE289608T1 (de) | 2005-03-15 |
| US5491237A (en) | 1996-02-13 |
| DE69534029T2 (de) | 2006-01-12 |
| AU2465195A (en) | 1995-11-29 |
| DE69532634D1 (de) | 2004-04-08 |
| ES2188661T3 (es) | 2003-07-01 |
| US6063923A (en) | 2000-05-16 |
| DK0758335T3 (da) | 2003-03-17 |
| EP0758335B1 (en) | 2002-11-06 |
| JPH09512558A (ja) | 1997-12-16 |
| ATE227292T1 (de) | 2002-11-15 |
| DE69528762D1 (de) | 2002-12-12 |
| WO1995029917A3 (en) | 1995-12-28 |
| ES2238523T3 (es) | 2005-09-01 |
| ES2219661T3 (es) | 2004-12-01 |
| HK1052687A1 (en) | 2003-09-26 |
| EP0758333B1 (en) | 2004-03-03 |
| DE69528762T2 (de) | 2003-07-17 |
| EP0758333A1 (en) | 1997-02-19 |
| EP0758335A1 (en) | 1997-02-19 |
| DE69534029D1 (de) | 2005-03-31 |
| EP1254908A1 (en) | 2002-11-06 |
| US5840898A (en) | 1998-11-24 |
| US6462196B1 (en) | 2002-10-08 |
| WO1995029917A2 (en) | 1995-11-09 |
| AU2381695A (en) | 1995-11-29 |
| DE69532634T2 (de) | 2005-03-10 |
| EP1254908B9 (en) | 2005-09-21 |
| WO1995029919A1 (en) | 1995-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6462196B1 (en) | Preparation of a camptothecin derivative by intramolecular cyclization | |
| KR100352212B1 (ko) | 4a,5,9,10,11,12-헥사히드로-6H-벤조푸로[3a,3,2-ef][2]벤즈아제핀유도체의제조방법 | |
| US4145434A (en) | Tetracyclic derivatives and pharmaceutical compositions of matter | |
| US5744605A (en) | Intermediates in the synthesis of (+) camptothecin and related compounds and synthesis thereof | |
| US6143891A (en) | Method for preparing camptothecin derivatives | |
| US6407229B1 (en) | Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine | |
| US5459269A (en) | 14-halo-camptothecins | |
| JP2561269B2 (ja) | 置換チアシクロアルケノ〔3,2−b〕ピリジン類 | |
| US6559309B2 (en) | Preparation of a camptothecin derivative by intramolecular cyclisation | |
| JPH07121931B2 (ja) | ベンゾ〔b〕フラン誘導体 | |
| HK1052687B (en) | Preparation of a camptothecin derivative by intramolecular cyclisation | |
| JP3017338B2 (ja) | インドールアルカロイド誘導体製造用の新規中間体化合物 | |
| US6716982B2 (en) | Method for preparing camptothecin derivatives | |
| JPH09506618A (ja) | スピロ環式ラクタムの製造方法 | |
| EP0251713A2 (en) | Enantioselective synthesis of 1,3,4,6,7,12B (S)- hexahydro-2H-bezo (B) furo (2,3-A) quinolizin-2-one | |
| JP2000044568A (ja) | 生理作用を有するジベンゾオキセピンおよびジベンゾチエピン誘導体の中間体 | |
| JPH07278453A (ja) | 3,3−ビスアリール−5−アザフタリドもしくは3,3−ビスアリール−7−アザフタリドの製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060104 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060404 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060529 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060509 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20060719 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060719 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061031 |